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http://www.biomedcentral.com/1472-6882/14/163RESEARCH ARTICLE Open AccessAn orally active immune adjuvant prepared from
cones of Pinus sylvestris, enhances the
proliferative phase of a primary T cell response
William Guy Bradley1*, Katharine Nichole Holm2 and Akiko Tanaka1Abstract
Background: We have previously demonstrated that an alkaline extract of shredded pinecones yields a
polyphenylpropanoid polysaccharide complex (PPC) that functions as an orally active immune adjuvant. Specifically,
oral PPC can boost the number of antigen-specific memory CD8+ T cells generated in response to a variety of
vaccine types (DNA, protein, and dendritic cell) and bias the response towards one that is predominately a T helper
1 type.
Methods: An immune response was initiated by intraperitoneal injection of mice with Staphylococcus enterotoxin B
(SEB). A group of mice received PPC by gavage three times per day on Days 0 and 1. The draining lymph nodes
were analyzed 48–96 h post-injection for the numbers of reactive T cells, cytokine production, the generation of
reactive oxygen species, and apoptotsis.
Results: In this study we examined whether the ability of PPC to boost a T cell response is due to an effect on the
proliferative or contraction phases, or both, of the primary response. We present data to demonstrate that oral PPC
significantly enhances the primary T cell response by affecting the expansion of T cells (both CD4 and CD8) during
the proliferative phase, while having no apparent effects on the activation-induced cell death associated with the
contraction phase.
Conclusions: These findings suggest that PPC could potentially be utilized to enhance the T cell response
generated by a variety of prophylactic and therapeutic vaccines designed to target a cellular response.
Keywords: Polyphenylpropanoid polysaccharide complex, Primary T cell response, Pine cone extractBackground
The health benefits of a pinecone extract were first doc-
umented by Pedanius Dioscorides [1]. Dioscorides (ca.
40-ca. 90) was an ancient Greek physician, pharmacolo-
gist and botanist who practiced in ancient Rome. In
about AD 65, after much direct observation of plants in
their native habitats and careful practical experience on
the medicinal uses of herbs, he wrote De Materia Medica.
De Materia Medica is a precursor to all modern pharma-
copeias and is one of the most influential herbal books in
history. Within the Materia Medica, Dioscorides describes
using extracts of pinecones to treat kidney and digestive* Correspondence: gbradley@tampabayresearch.org
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reproduction in any medium, provided the orailments and to apply to the skin to treat a disease that
appears to have been psoriasis.
For much of the last century, the Japanese inhabitants
of the island of Kyushu have also known about the me-
dicinal properties of a pinecone extract [2]. They have
used an aqueous extract (tea) prepared from pinecones to
treat illnesses ranging from infectious disease to cancer.
Because of the indigenous beliefs that the pinecone tea
was able to treat such a wide variety of illnesses, it ap-
peared to us that the effects of the extract were very likely
being mediated through the immune system.
Previous studies indicate that an orally active polyphe-
nylpropanoid polysaccharide complex (PPC) derived
from the cones of Pinus sylvestris not only biases the im-
mune response initiated by DNA, protein, or dendritic
cell vaccines towards one that is predominately a TLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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generation of antigen-specific CD8+ cytotoxic T cells de-
tected during a secondary T cell response [3]. In vitro
studies have revealed that the exposure of human PBMC
[4] or murine bone marrow cells [5] to PPC rapidly in-
duces the production of dendritic-like cells.
The ability to induce a predominant Th1 response when
delivered at the time of immunization is coupled with the
ability to suppress the development of an antigen-specific
Th2 response [3]. Oral delivery of PPC at the time of
immunization with the model Th2 antigen, chicken egg
ovalbumin (OVA), blocks the development of an IgE-
mediate allergic response to OVA. In vitro this is detected
as an inability of OVA-stimulated splenocytes to produce
IL-4 while producing significantly elevated amounts of
IFNγ [3]. When the levels of OVA-specific CD8+/IFNγ+ T
cells in these mice are measured by ELISPOT, the mice re-
ceiving PPC at the time of immunization consistently yield
twice as many of these cells [3].
With the continual accumulation of anecdotal reports
suggesting that use of PPC along with traditional anti-
cancer therapies somehow enhances the ability to mount
an effective anti-cancer response, we are motivated to
better understand PPC's mechanism of action. In the
study described herein, we determined that PPC’s associ-
ation with an increased number of antigen-specific CD8+
CTL activated during a secondary T cell response is very
likely due to its ability to significantly enhance the expan-
sion of these cells during the early phase of the primary T
cell response and not by affecting the contraction phase
or rate of activated induced cell death.
Methods
Animal care
Six to seven week old male Balb/c mice were obtained
from Charles River Laboratories and housed 3–5 mice per
cage in a self-contained ventilated cage system (Innovive
Inc., San Diego,CA) maintained at 40 air changes per
hour. Both the intake and exhaust air were HEPA filtered.
Mice were maintained in an environment of 22˚C with a
12 h light/12 h dark cycle. The mice were fed ad libitum a
standard diet containing 22% crude protein and 5% fat
(Harlan Teklad Laboratory, cat no 8640) and provided
water ad libitum. This study was carried out in strict ac-
cordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Insti-
tutes of Health. The protocol was approved by the Tampa
Bay Research Institutional Animal Care and Use Commit-
tee (protocol number: 2011–001).
Preparation of PPC
Powdered PPC was kindly provided by Allera Health
Products, Inc. (360 Central Avenue, Suite 1560, St.
Petersburg, FL 33701). The pinecones used by Allera toproduce PPC were obtained from a commercial supplier
of Scotch pine (Pinus sylvestris) (identification of the sup-
plier is regarded as proprietary information). Identification
of the specific species of pine was performed by a quali-
fied employee of the supplier. The pinecones were
washed extensively in deionized water and then shred-
ded. The pinecone shreds were then loaded into a stain-
less steel reaction vessel and extracted with water at
elevated pH (12.0) and temperature (121°C, 30 min).
The resulting extract was standardized by UV spectros-
copy at a wavelength of 280 nm and by a series of bio-
logical assays. The liquid was tested extensively to
ensure that it did not contain contaminants such as her-
bicides, pesticides, heavy metals, endotoxin, or microor-
ganisms and was then spray-dried to form a dark brown,
odorless, stable powder. The powdered extract was sus-
pended in sterile water to a stock concentration of 25 mg/
mL (w/v), centrifuged at 10,000 × g for 20 minutes to re-
move particulates and then filtered through a 0.2 μm
nylon filter. The OD280 of the solution was measured and
used to define the concentration of active ingredients:
PPC conc mg=mLð Þ ¼ OD280 1=22:8L gram−1  cm−1
 
where 22.8 L⋅gram−1⋅cm−1 is the extinction coefficient
for polyphenylpropanoids. A working stock containing
200 μg/mL of polyphenylpropanoids diluted in sterile
distilled water was prepared fresh each week.
In Vivo immune stimulation
On Day 0, three mice each in the SEB and SEB + PPC
groups were injected intraperitoneally (i.p.) with 100 μg of
Staphylococcal enterotoxin B (SEB, Sigma Chemical Com-
pany, St. Louis, MO) dissolved in 100 μL phosphate buff-
ered saline (PBS), pH 7.4. Three mice in the Naive group
were injected i.p. with 100 μL PBS, pH 7.4. The mice in
the SEB + PPC group were gavaged with 100 μL of a
200 μg/mL solution of PPC three times daily on Day 0
and Day 1 for a total of 6 doses. At 48 or 96 hours post-
SEB immunization, the mice were euthanized by CO2
inhalation. The set of inguinal lymph nodes from each
mouse was pooled and used in each assay. Therefore,
the results reported from lymph node cells represent
the collection of data points from each mouse. The
number of cell subsets per lymph node was obtained
from the set of pooled inguinal lymph nodes and then
dividing that number by two. To calculate the total
number of cell subsets per lymph node, the percent of
each subset was multiplied by the total number of cells
isolated from the lymph nodes. The total number of cells
isolated from the lymph nodes was determined using
the Millipore Muse cell counter. Serum was collected
for quantification of various cytokines and was stored
at −80°C until analyzed.
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Standard ELISA development kits specific for murine
IL-2, IFNγ, and IL-12p70 were purchased from Pepro-
tech (Rocky Hill, NJ). The detection of serum IL-2, IFNγ,
and IL-12p70 was performed according to the manufac-
turer’s instructions. The absorbance of the final product
was measured using BioTek’s μQuant plate spectropho-
tometer at a wavelength of 450 nm. Standard curves
were prepared using Prism’s GraphPad software (Graph-
Pad Software, Inc., La Jolla, CA).Lymph node and spleen cell isolation
Isolated inguinal lymph nodes and spleens were homog-
enized in a sterile plastic bag containing 4 mL Hanks
balanced salt solution (HBSS) pH 7.4, using a Seward
Stomacher®80 with settings of medium speed for 60 sec-
onds. The resulting cell suspensions were pelleted and
then suspended in 2 mL HBSS (for lymph node cells) or
4 mL HBSS (for spleen cells). The yield of cells was deter-
mined by mixing 20 μL cells with 380 μL of Millipore’s
Muse Count and Viability stain. The cell concentration and
number of viable cells was determined using the Muse Cell
Analyzer (Millipore). The cells were pelleted and then sus-
pended in enough complete media (RPMI 1640 containing
10% fetal calf serum and 1x penicillin/streptomycin) to pro-
vide a final concentration of 4 × 106 cells/mL.Flow cytometry
For each mouse, 1×106 lymph node cells were added to
a 1.5 mL microfuge tube and then pelleted by centrifu-
gation for 1 minute at 1000 × g. The pelleted cells were
placed on ice and then suspended in 100 μL of FACS
buffer (PBS containing 10% fetal bovine serum and 0.1%
sodium azide) containing 1 μL anti-CD16/32 Fc blocking
antibody (clone 93). Ten minutes later 1–5 μL of fluor-
escent antibodies specific for cell surface antigens were
added. The fluorescent anti-mouse antibodies used to
detect the SEB-activated T lymphocytes were as follows:
CD3 (clone 17A2) labeled with allophycocyanin (APC),
CD4 (clone GK1.5) labeled with fluorescein isothiocyan-
ate (FITC), CD8 (clone SK1) labeled with phycoerythrin
(PE), and Vβ8 (clone KJ16-133) labeled with a propri-
etary peridinin chlorophyll protein conjugated with
eFluor710 (PerCP-eFluor®710). All of the antibodies were
purchased from eBioscience, San Diego, CA. The cells
were incubated on ice for 30 min and then washed by
adding 500 μL FACS buffer and pelleting the cells at
1000 × g for 2 min. The pelleted cells were then sus-
pended in 200 μL FACS buffer and analyzed by flow cy-
tometry using a BD FACSCalibur (Becton Dickinson,
San Jose, CA) equipped with CellQuest Pro software.
The FACS data was further analyzed using FloJo soft-
ware (TreeStar Inc, Ashland, CA).Detection of apoptosis
Annexin V staining was performed according to the
protocol provided with eBioscience’s Annexin V Apop-
tosis Detection Kit. Isolated lymph node cells (1 × 106/
mouse) were suspended in Annexin V staining buffer
containing 1 μL APC-labeled anti-CD3, 5 μL PerCP-
eFluor®710-labeled anti-Vβ8, and 1 μL FITC-labeled
Annexin V to identify T cells undergoing apoptosis. The
cells were incubated at room temperature for 10 min
and then washed in binding buffer. The cells were sus-
pended in binding buffer and then analyzed by flow
cytometry.
Detection of reactive oxygen species
To detect the presence of reactive oxygen species in acti-
vated T cells, isolated lymph node cells from each mouse
were exposed to Invitrogen’s CM-H2DCFDA (5-(and-6)-
chloromethyl-2’,7’-dichlorodihydrofluorescein diacetate,
acetyl ester). CM-H2DCFDA passively diffuses into cells
where its acetate groups are cleaved by intracellular ester-
ases and its thiol-reactive chloromethyl group reacts with
intracellular glutathione and other thiols. Oxidation then
produces a fluorescent adduct that cannot escape the cell.
The resulting fluorescence was then measured by flow cy-
tometry. Isolated lymph node cells (1 × 106/mouse) were
exposed to 100 μL FACS buffer containing 1 μL APC-
labeled anti-CD3 antibody, 5 μL PerCPeFluor®710-labeled
anti-Vβ8 antibody and 2 μL of a 50 μM solution of CM-
H2DCFA for 15 min at 37˚C. The cells were then washed
with 500 μL FACS buffer, pelleted and suspended in
200 μL FACS buffer. The levels of fluorescence within
the various cell samples were measured by flow cytome-
try. The resulting data is shown as the percentage of
ROS+ lymph node T cells (CD3+) and as the frequency
distribution (histogram) of ROS levels in lymph node
CD3+ T cells in SEB and SEB + PPC treated mice.
Detection of intracellular Bcl-2
To detect the intracellular levels of the anti-apoptosis re-
lated protein, Bcl-2, cells previously stained with APC-
labeled anti-CD3 and PerCPeFluor®710-labeled anti-Vβ8
antibodies were washed in 0.03% saponin dissolved in
HBSS (HBSS-SAP) and then pelleted by centrifugation
at 1000 × g for 2 minutes. The cell pellets were sus-
pended in 100 μL HBSS-SAP containing 1 μL FITC-
labeled anti-Bcl-2 antibody (clone 10C4, eBioscience),
and incubated on ice for 60 minutes. The cells were
washed twice with 500 μL HBSS-SAP buffer and then
once with HBSS only. The cells were then suspended in
200 μL HBSS and analyzed by flow cytometery.
Analysis of gene expression
Total RNA was isolated from lymph node cells using
Qiagen’s RNeasy Plus Mini Kit following the manufacturer’s
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RNase-free water and the yield of RNA was determined by
spectrophotometry at an optical density of 260 nm.
One microgram of total RNA was reverse-transcribed
into cDNA using the QuantiTect Reverse Transcription
kit from Qiagen (Valencia, CA) and by following the
manufacturer’s instructions. SABiosciences’ (Valencia,
CA) RT2 Profiler qPCR SYBR green master mix kit was
used for the real time quantitative PCR (qPCR). One
microliter of the cDNA per reaction was added to a
1.5 mL microfuge tube containing 12.5 μL 2x SYBR
green/fluorescein master mix and 10.5 μL H2O per reac-
tion needed. Validated primer pairs from SABiosciences'
RT2 qPCR Primer Assays specific for murine Bcl-2, Bcl-
3, Bcl-xL, Bax, and Bim were utilized. These primers are
pre-mixed at a concentration of 10 μM. One microliter
of each primer pair was placed in duplicate wells of a 96
well PCR plate and then 24 μL of the cDNA/SYBR
green master mix was added to the appropriate wells.
Once all the samples had been added to the plate the
plate was covered with clear plastic film and then cen-
trifuged at 200 × g for 1 min to mix and collect all of
the solutions in the bottom of the wells. The plate was
then placed in a BioRad (Hercules, CA) iCycler pro-
grammed to run one cycle of 10 min at 95˚C to activate
the polymerase and then 40 cycles of [95˚C × 15 sec→
60˚C × 1 min] to amplify the gene-specific cDNA. The
relative levels of mRNA expression were normalized to
the mouse β-actin housekeeping gene expressed in
lymph node cells from naive (untreated) mice and deter-
mined by the ΔΔ-Ct method [6].
Statistical analysis
The significance of responses to the multiple treatments
was determined by ANOVA using Newman-Keuls mul-
tiple comparison test provided in GraphPad’s Prism®
software (GraphPad Software, Inc, La Jolla, CA). All ex-
periments were performed at least 3 times. Error bars on
the graphs represent the standard deviation and demon-
strate the ability to detect statistical significance when
using only 3 mice per group.
Results
Oral delivery of PPC enhances the number of CD4+/ and
CD8+/Vβ8+ T cells in the lymph nodes of mice during the
primary response to SEB
Previous studies have shown that the injection of SEB spe-
cifically induces the proliferation of murine CD3+/Vβ8+ T
cells in a dose-dependent manner during a primary T cell
response (Figure 1) [7]. To determine if PPC would en-
hance this proliferative response to SEB, mice (3 per
group) were divided into four experimental groups.
While the naive groups received no treatment, the SEB
group received an i.p. injection of 100 μg SEB on Day 0,and the SEB + PPC group received an i.p. injection of
SEB on Day 0 that was immediately followed by gavage
with 100 μL of a 200 μg/mL solution of PPC. This gav-
age was repeated two more times on Day 0 and then
three times (10 am, 1 pm, and 4 pm) on Day 1. Starting
on Day 0 the mice were also supplied 200 μg/mL PPC
in their water ad libitum. PPC was also supplied in this
manner to the PPC only group of mice. This experi-
mental protocol was repeated several times for dura-
tions of 48 hours to determine if PPC affected cell
activity during the proliferation phase of the primary T
cell response.
At the height of T cell proliferation, 48 hours post SEB
injection, significantly more CD3+/Vβ8+ T cells were iso-
lated from the inguinal lymph nodes of mice treated
with SEB + PPC (Figure 2A, p < 0.05). This PPC associ-
ated enhancement of lymph node T cells was detected in
both the CD4+/Vβ8+ (p < 0.01) and CD8+/Vβ8+ popula-
tions (p < 0.01) (Figure 2B and 2C, respectively). Interest-
ingly, administration of PPC alone had no effect on the
numbers of CD3+/, CD4+/, or CD8+/Vβ8+ T cells (p >
0.05 for all three populations of Vβ8+ T cells when com-
paring Naïve versus PPC only) (Figure 2).
PPC enhances the number of CD8+/Vβ8+ T cells surviv-
ing the contraction phase of the primary T cell response
Separate groups of mice were treated as described above
and then at the peak of the contraction phase (Figure 1),
96 h post i.p. injection of 100 μg SEB, the inguinal lymph
node Vβ8+ T cells were enumerated by flow cytometry to
determine if oral delivery of PPC affected this phase of the
primary response. As shown in Figure 3 (left panel), by
96 h the numbers of CD3+/CD4+/Vβ8+ T cells in the SEB
and SEB + PPC groups had contracted to levels no differ-
ent than that found in the Naïve group (p > 0.05). How-
ever, the numbers of CD3+/CD8+/Vβ8+ T-cells remained
elevated in both the SEB (Figure 3, right panel; p < 0.01
compared to the Naïve group) and SEB + PPC treated
groups (p < 0.05 when compared to the SEB group). This
seemingly enhanced susceptibility of CD4+ cells to acti-
vation induced cell death (AICD) has been reported by
others and is not specific for the response to superanti-
gens [8,9]. As observed in the 48 h samples, treatment
with PPC was associated with a significant increase in
CD8+/Vβ8+ T cells when compared to the samples from
mice receiving only the SEB injection (p < 0.05, Figure 3,
right panel).
PPC reduces serum IL-2 and enhances IFNγ levels 48 h
post immunization
To determine if oral administration of PPC was affect-
ing the production of cytokines associated with T cell
activation and expansion, we examined the serum from
each mouse in the various treatment groups for the
presence of IL-2, IFNγ, and IL-12p70. The results reveal
Figure 1 Kinetics of the primary T cell response. In the primary response to antigen, naive T cells undergo a massive proliferative burst of
expansion that creates short-lived effector cells. This proliferative phase is then followed by a contraction phase in which the majority (90–95%) of
the antigen-specific T cells undergo apoptosis, leaving behind a stable memory population.
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crease in the serum levels of all three cytokines (Figure 4).
The serum from mice receiving PPC along with the SEB
immunization were found to have less IL-2 (p < 0.05),
more IFNγ (p < 0.005), and no significant change in the
levels of IL-12p70 (Figure 4).Figure 2 Expansion of Vβ8+ T cells in SEB + PPC treated mice after 48
SEB only (SEB), gavaged with 100 μL PPC at a concentration of 200 μg/mL
of PPC at 200 μg/ml TID for 2 days (SEB + PPC). The SEB + PPC and PPC on
ad libitum for 48 hours. Naive mice received an i.p. injection of PBS. (A) The
CD3+/CD8+/Vβ8+ cells per lymph node are shown. Error bars represent staPPC reduces the levels of ROS in SEB activated CD3+
lymph node T cells 48 h post immunization
Since the increase in reactive oxygen species (ROS) pro-
duced by activated T cells is necessary for the induction
of apoptosis during the contraction phase of the primary
T cell response [10], the levels of ROS in the lymph nodehours. Balb/c mice (n = 3 per group) were injected i.p. with 100 μg
(PPC only) or injected i.p. with 100 μg SEB and gavaged with 100 μL
ly mice were also provided PPC at 200 μg/mL in their drinking water
total number of CD3+/Vβ8+ cells, (B) CD3+/CD4+/Vβ8+ cells, and (C)
ndard deviation.
Figure 3 Levels of Vβ8+ T cells in the inguinal lymph nodes 96 h post SEB injection. Balb/c mice (n = 3 per group) were treated as
described in the Materials and Methods. (A) The total number of CD4+/Vβ8+ cells and (B) CD3+/CD8+/Vβ8+ cells per lymph node are shown.
Error bars represent standard deviation.
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mined. As shown in Figure 5 (left panel), oral delivery of
PPC significantly reduced the percentage of CD3+/ROS+
T cells obtained from SEB treated mice (p < 0.01) and
significantly reduced the levels of ROS per individual
CD3+ T cells (Figure 5, right panel). This would suggest
that molecules in PPC might be functioning as antioxi-
dants in vivo. If this is true, PPC could be affecting the
ability of ROS to induce apoptosis in the activated T
cells. For these reasons the expression of several apop-
tosis related genes was investigated.
PPC’s effect on the expression of the anti-apoptotic
protein, Bcl-2, 48 hr post immunization
Hildeman et al. revealed that the ROS production by T
cells activated with SEB results in the suppression of Bcl-2
mRNA and protein expression [11]. The suppression of
Bcl-2 expression reduces the Bcl-2/Bim ratio and allows
unbound Bim to interact with Bax and create the apopto-
some [12]. If T cells are activated in the presence of an
antioxidant the levels of Bcl-2 mRNA and protein increase
and lead to significant inhibition of ACID [13]. Since PPC
appeared to have reduced the levels of ROS in SEB acti-
vated T cells, we sought to determine if this was also asso-
ciated with a concomitant increase in Bcl-2 mRNA or
protein expression. While PPC appeared to enhance the
percentage of CD3+/Vβ8+ T cells positive for the intra-
cellular expression Bcl-2 protein (p < 0.05; Figure 6A),
this was found to be due to the increased number of
CD3+/Vβ8+ T cells in the PPC-treated mice rather than
an increase in the level of Bcl-2 protein per cell (Figure 6B).
When individual Vβ8+ T cells were examined, the T cells
from mice in both the SEB and SEB + PPC groups con-
tained equally reduced amounts of intracellular Bcl-2
protein (Figure 6B). Bcl-2 levels in Vβ8 negative cells ap-
peared not to be affected by SEB or SEB + PPC (Figure 6C).
These results suggest that the reduction of ROS levels
detected in the SEB + PPC-treated mice was not likely
to have affected the induction of apoptosis.The reduction of Bcl-2 protein levels in the SEB and
SEB + PPC groups was paralleled by a reduction in the
levels of Bcl-2 specific mRNA detected in the lymph
nodes (Figure 7A). The treatment of naïve mice with
PPC only also resulted in a reduction in the expression
level of Bcl-2 mRNA. This would suggest that PPC most
likely does not function as an antioxidant in vivo and ex-
erts little effect on the pattern of activation induced
apoptosis.
PPC’s effect on the expression of mRNA for Bcl-3, Bim,
and Bax
Overexpression of the NFkB activator, Bcl-3, is associ-
ated with enhanced survival of activated T cells. Cyto-
kines from adjuvant activated dendritic cells enhances
the expression of Bcl-3 mRNA [14]. In the SEB and SEB +
PPC treated mice we observed no significant effect of PPC
on the levels of the Bcl-3 mRNA (Figure 7A). This also sug-
gested that PPC was not affecting the expression of anti-
apoptosis genes.
However, there was observed an almost 4-fold increase
in Bcl-3 mRNA in the lymph nodes of mice treated with
only PPC (Figure 7B). In the study by Mitchell et al. [15]
neither Bcl-2 nor Bcl-xL expression in T cells was found
to be correlated with activation induced survival (AIS).
In their paper further analysis showed that neither the
extent of T cell proliferation nor the reactive oxygen
content of T cells was affected in a way that could ex-
plain AIS. Finally, they showed that microarray analyses
pointed toward the expression of Bcl-3 as an important
mediator of AIS in T cells [15]. Our results suggest that
while PPC can enhance expression of Bcl-3 mRNA in
naïve mice, it apparently cannot influence Bcl-3 expres-
sion in SEB-activated T cells.
While the mRNA levels for the pro-apoptosis protein,
Bax, did not appear to be significantly affected by SEB
or SEB + PPC treatment (Figure 7A), the levels of mRNA
for the pro-apoptosis Bcl-2 binding protein, Bim, were
found to be elevated almost 4-fold in the lymph nodes
Figure 4 Serum cytokine levels in mice 48 h post i.p. injection
of SEB. Mice were injected i.p. with 100 μg SEB. One group was
provided PPC (200 μg/mL) in their drinking water for 48 h (blue
bars). Naive mice received an i.p. injection of PBS (red bars). After
48 h serum was obtained and examined by ELISA for the levels of
IL-2 (panel A), IFNγ (panel B), and IL-12p70 (panel C). Error bars
represent standard deviation.
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(Figure 7A). The administration of PPC alone did not
appear to affect the expression of Bim (Figure 7B). These
observations support the conclusion that the pattern of
AICD is clearly detected in the SEB treated mice and
that administration of PPC to these mice does not ap-
pear to significantly suppress the activation inducedapoptosis associated with the contraction phase of T cell
activation.
PPC does not suppress SEB-enhanced apoptosis
When the lymph node Vβ8+ T cells were examined by
Annexin V staining, an early sign of apoptosis, there was
revealed to be a significant difference between the Naïve
and SEB treated groups (Figure 8, p < 0.001) demonstrat-
ing the SEB-associated induction of apoptosis. However,
there was no difference (p > 0.05) in the levels of apop-
tosis in the cells isolated from the SEB or SEB + PPC
groups of mice. This again suggests that PPC does not
play a major role in suppressing the apoptosis associated
with the contraction phase of the primary T cell re-
sponse to SEB.
Discussion
The report by Burrows et al. [3] describes the ability of
orally administered PPC to consistently double the num-
ber of antigen-specific CD8+/IFNγ+ T cells detected dur-
ing secondary T cell responses in mice that had been
immunized with either a DNA, protein or dendritic cell
vaccine. All of these T cell responses were measured at
times long after the primary response had waned and
memory cells had been established [3]. In order to de-
termine if PPC’s activity is specific for the secondary
response, we sought to examine its effect on the devel-
opment of a primary T cell response. To do so, we uti-
lized the well-established SEB model of T cell activation.
When SEB is presented by MHC II bearing APC to
Vβ8+ T cells, the T cells become activated, begin prolifer-
ating, and undergo differentiation. This takes place with-
out the need for antigen processing by the APC. When
we examined the effects of oral PPC on the SEB-
mediated Vβ8+ T cell expansion we detected significantly
more CD4+ and CD8+ Vβ8+ T cells in the lymph nodes
of mice that had been treated with SEB + PPC. In fact,
we again observed a doubling of the number of CD4+/Vβ8+
and CD8+/Vβ8+ T cells in the lymph nodes of PPC treated
mice (Figure 2). Interestingly, treatment of mice with oral
PPC alone appeared to have no effect on T cell expansion
(Figure 2). These observations suggest that the PPC effect
we previously observed during the secondary T cell re-
sponse is likely to due to PPC’s ability to affect the primary
response.
By 96 h post SEB injection, when the activated T cells
are in the midst of contraction, the CD4+/Vβ8+ T cells
in the SEB treated mice had already contracted to levels
lower than those found in the lymph nodes of naive
mice while the levels of CD8+/Vβ8+ T cells in the SEB +
PPC treated mice were still significantly higher than those
found in the mice treated with SEB alone (Figure 3). This
finding of an apparent increased contraction rate in the
activated CD4+ T cells has been previously described and
Figure 5 ROS levels in CD3+ lymph node T cells 48 h post SEB injection. Balb/c mice (n = 3 per group) were treated as described in the
Materials and Methods. (A) The percentage of CD3+/ROS+ lymph node T cells from each treatment group are shown. (B) The effect of PPC on
the level of ROS per CD3+ lymph node T cell in the SEB (red line) and SEB + PPC groups (blue line) are shown. Error bars represent
standard deviation.
Figure 6 Intracellular levels of Bcl-2 in Vβ8+ lymph node T cells 48 h post SEB injection. Balb/c mice (n = 3 per group) were treated as
described in the Materials and Methods. The number of intracellular Bcl-2+/Vβ8+ lymph node T cells from the Naive (red line), SEB (purple line),
and SEB + PPC groups (blue line) are shown in the bar graph (panel A) and the histogram in panel B. Error bars in panel A represent standard
deviation. The histogram in panel C depicts the number of intracellular Bcl-2+/Vβ8− cells detected in the lymph nodes from the different
treatment groups.
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Figure 7 Expression of Bcl-2, Bcl-3, Bax and Bim mRNA in lymph nodes 48 h post SEB injection. Balb/c mice (n = 3 per group) were
treated as described in the Materials and Methods. (A) mRNA from naïve, SEB or SEB + PPC treated mice was analyzed for the expression of Bcl-2,
Bcl-3, Bax, and Bim, while (B) expression of the same genes in mice treated with PPC only were analyzed. Total cell RNA was pooled from the
lymph nodes of Naïve, SEB and SEB + PPC treated mice and then converted to ssDNA. Duplicate samples from each group were used for RT-PCR.
The fold change in RNA levels for each gene was determined using the ΔΔ-Ct method and β-actin as the expression control.
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resulting enhanced expansion of the SEB + PPC sti-
mulated CD4+/Vβ8+ T cell population did not lead to an
enhanced number of CD4+/Vβ8+ T cells surviving the
contraction is curious (Figure 3A). We believe that this
observation could be explained by the findings of Liu
and Janeway [17], Noble et al. [18], Florido et al. [19],
and Atsumi et al. [20]. Their reports describe a strong
link between the production of IFNγ by activated CD8+
T cells and the induction of CD4+, but not CD8+, T cell
apoptosis. Therefore, the increase in serum IFNγ levels
that we detected (Figure 4) could potentially result in a
more extensive induction of apoptosis in the CD4+/Vβ8+
T cell population.
There have been reports suggesting that the production
of reactive oxygen species by activated T cells is respon-
sible for the induction of apoptosis [12], [21]. Specifically,
it has been shown that the ROS associated with T cellFigure 8 Detection of early apoptosis in the lymph node Vβ8+ T cells
treated as described in the Materials and Methods. The cells were stained f
flow cytometry. (A) The scatter plots of the Vβ8+/Annexin V+ T cells from t
Annexin V+ cells in the CD3+/Vβ8+ population of lymph nodes cells is show
significant difference between the two groups and a p value > 0.05.activation works by down regulating the activity of the
anti-apoptosis protein, Bcl-2 [12]. Since levels of Bcl-2
within cells are critical for anti-apoptotic activity, decreas-
ing Bcl-2 sensitizes cells to apoptosis. Antioxidants cap-
able of scavenging the ROS have been shown to be able to
prevent the ROS-induced down regulation of Bcl-2 and
prevent activation induced apoptosis [12].
In 2003, Philippa Marrack’s laboratory discovered that
culturing activated T cells (48 hr post SEB treatment)
with the peroxynitrite scavenger, MnTBAP, reversed the
ROS-induced decline in Bcl-2. They also demonstrated
that the pro-apoptosis protein Bim (Bcl-2 interacting
mediator of cell death) is required for SEB-driven T cell
death and that it is the ROS-induced down regulation of
Bcl-2 that leads to increased levels of free Bim. It is the
free Bim that alters the mitochondrial membrane poten-
tial and activates the apoptosis pathway [12]. Therefore,
suppression of the ROS in activated T cells should lead48 h post injection of SEB. Balb/c mice (n = 3 per group) were
or the expression of CD3, Vβ8 and Annexin V and then evaluated by
he lymph nodes of the individual mice are shown. (B) The percent of
n. Error bars represent standard deviation. The label (ns) indicates no
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prevent activation of the apoptosis pathway.
Since PPC contains polyphenolics with antioxidant
properties [22], we sought to determine if PPC was af-
fecting the generation of ROS by the SEB-activated T
cells. As shown in Figure 5, orally administered PPC
was able to reduce the ROS levels in the lymph node
CD3+ T cell population. When we examined the levels
of intracellular Bcl-2 in the Vβ8+ T lymph node T cells,
we found that PPC had no effect on SEB’s suppression of
Bcl-2 expression. The T cells from both the SEB and SEB +
PPC treated mice had less Bcl-2 per cell than did the
cells from the naive control animals (Figure 6). This
suggests that the observed decrease in ROS levels by
PPC were probably not significant enough to affect the
expression of Bcl-2. When the CD3+/Vβ8− T cells (cells
that should not be activated by SEB) were examined
there was found to be no difference between the intra-
cellular levels of Bcl-2 in the lymph nodes from the
Naive mice and the SEB or SEB + PPC groups (Figure 6C).
The lack of an effect by SEB on the CD3+/Vβ8− cells dem-
onstrates the specificity of SEB for T cells expressing the
Vβ8+ variant of the T cell receptor.
The reduction of intracellular Bcl-2 protein levels de-
tected in the SEB and SEB + PPC groups was paralleled
by changes in the mRNA levels for Bcl-2 (Figure 7A). In
the same cells we found that while SEB suppressed ex-
pression of the anti-apoptotic gene, Bcl-2, it enhanced
expression of the pro-apoptosis gene, Bim, by more than
3 fold (Figure 7A). These results are in agreement with
those of Hildeman et al. [11] and indicate that activation
induced apoptosis had already begun to occur 48 h after
injection of the SEB.
Activation of cell apoptosis at the 48 h time point was
verified by Annexin V staining. Cells undergoing apoptosis
can be identified by their ability to bind fluorescently la-
beled Annexin V. When compared with the T cells from
the Naive mice, SEB significantly enhanced the percentage
of Annexin V positive Vβ8+ T cells (p < 0.001). Adminis-
tration of PPC to the SEB treated mice failed to alter SEB’s
ability to enhance the expression of Annexin V (Figure 8).
When combined with the other indicators of activation
induced cell death, it appears that PPC has no signifi-
cant effect on the contraction phase of the primary T
cell response.
Conclusions
PPC’s ability to double the number the antigen-specific
CD8+ T cells detected in a secondary immune response
following immunization with either DNA, protein, or
dendritic cell vaccines appears to be associated with
enhancement of the proliferative phase of the primary
T cell response. Previous reports from our laboratory
demonstrated that the in vitro exposure of human PBMC[4] and murine bone marrow cells [5] to PPC enhances
the production and maturation of dendritic cells. If PPC is
able to similarly affect dendritic cells in vivo it is possible
that this could result in enhanced activation and prolifera-
tion of the SEB-specific T cells. Another possibility is that
PPC could be enhancing dendritic cell migration to the
lymph nodes. The presence of an increased number of
dendritic cells would allow for the presentation of SEB to
a larger number of T cells. Since not all Vβ8+ T cells pro-
liferate in response to an SEB injection [23], an increase in
the number of dendritic cells presenting SEB in the lymph
nodes could result in an increased number of activated T
cells. In fact, preliminary results have detected an increase
in the number of CD11c+ cells in the lymph nodes of mice
treated with SEB + PPC (data not shown). Further studies
are needed to identify the mechanism(s) by which PPC
enhances the proliferative phase of a primary T cell
response.
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